Julius Clinical appoints Stefan Timmerman as new Chief Financial Officer
Zeist, Netherlands, April 22, 2024 — We proudly welcome Stefan Timmerman as our new Chief Financial Officer (CFO), effective April 1st, following up Eelco Brouwer, who played a crucial role in the completion of the Ampersand transaction last year.
Stefan Timmerman brings a wealth of experience to our team, with a background across large and medium-sized corporations, as well as private equity ventures. His hands-on approach and analytical mindset make him a valuable asset. Stefan Timmerman’s collaborative nature fosters effective teamwork and supports our organizational goals.
We believe Stefan Timmerman’s expertise will play a key role in driving our company towards its strategic objectives. He is passionate about optimizing processes to align with our mission of advancing clinical research and enhancing healthcare outcomes globally.
Following his appointment, Stefan Timmerman enthusiastically expressed his dedication, stating, “Since I have become active in the health care industry, I am passionate to work for a company that ultimately can make a difference in the life of patients. As CFO, I am only able to indirectly contribute. However, by supporting the organization with in-depth management information and by creating a financial healthy organization, we can further enhance global clinical studies to diseases patients are suffering today’’.
Martijn Wallert, CEO of Julius Clinical, expressed his confidence in Timmerman’s appointment, stating, “I am delighted to welcome Stefan Timmerman to our team as the new CFO. Stefan’s proven track record in finance and strategic development across various industries is exactly what we need to advance our mission. His insight and dedication will undoubtedly enrich our company and I’m convinced that with Stefan’s experience we will be even better able to realize our growth ambitions.”
Stefan Timmerman’s appointment represents a next step for Julius Clinical in its mission of advancing clinical research and enhancing healthcare outcomes globally.
For media inquiries, please contact marketing@juliusclinical.com
About Julius Clinical Research
Julius Clinical Research, founded in 2008 and based in Zeist, The Netherlands, is a scientifically focused CRO providing end-to-end clinical trial service to pharmaceutical and biotechnology customers, as well as governments and academia. Julius Clinical’s renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a global network of research sites to deliver tailor-made solution for customers and their clinical trials. With a focus on the therapeutic areas of neurology, renal, cardiometabolic and infectious diseases, Julius Clinical has grown to approximately 200 employees and has supported over 130 clinical trials, enrolling more than 200,000 participants in around 40 countries. Learn more about Julius Clinical Research at www.juliusclinical.com.
Related news
Insights from the CLEAR trial outcomes on MASLD and heart health
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
Julius Clinical welcomes Ricard Quingles Blasi as new Chief Business Officer
Zeist, Netherlands, April 5, 2024 — We’re proud to announce the appointment of Ricard Quingles Blasi as our new Chief Business Officer (CBO). With over 25 years of dynamic leadership experience, Ricard Quingles Blasi brings a wealth of strate...
Metabolic dysfunction associated steatotic liver disease and the heart
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...